The United States is seeing a major change in how people can access GLP-1 weight-loss medications. This is happening because of a new Medicare pilot program and a federal court decision that prevents states from limiting the prices of certain drugs.

美國目前在人們獲取 GLP-1 減重藥物的方式上正經歷重大變化。這是由於一項新的 Medicare 試行計劃，以及一項防止各州限制某些藥物價格的聯邦法院裁決。

The Medicare GLP-1 Bridge Program is a one-year project started by the Trump administration that has changed the cost of obesity treatments. Starting July 1, eligible people—those with a body mass index (BMI) of 35 or higher, or 27 with other health issues—can get medications like Foundayo, Wegovy, or Zepbound for a $50 co-payment. Experts from KFF estimate that about four million people may qualify for this help. Furthermore, more private employer insurance plans are covering these drugs; for example, Eli Lilly reported that coverage rose from 20% to 67%.

Medicare GLP-1 Bridge Program 是由川普政府啟動的一年期計畫，改變了肥胖症治療的成本。從 7 月 1 日開始，符合資格的人士——即身體質量指數 (BMI) 為 35 或更高，或 BMI 為 27 且有其他健康問題的人——可以以 50 美元的共付額購買如 Foundayo, Wegovy 或 Zepbound 等藥物。KFF 的專家估計，約有四百萬人可能符合這項援助資格。此外，更多私人雇主保險計劃開始承保這些藥物；例如，禮來 (Eli Lilly) 報告指出承保率從 20% 上升至 67%。

At the same time, the pharmaceutical industry won a legal battle regarding price controls. A federal judge stopped the Colorado Prescription Drug Affordability Board from setting a maximum price for Amgen's drug, Enbrel. The judge argued that such a price cap would likely cause significant harm to the company. Although several states have created similar boards to lower medication costs, Colorado's attempt to set price limits has been blocked by the court.

與此同時，製藥業在價格控制的法律鬥爭中獲勝。一名聯邦法官阻止了科羅拉多州處方藥可承受能力委員會 (Colorado Prescription Drug Affordability Board) 為安森元 (Amgen) 的藥物 Enbrel 設定最高價格。法官認為，這樣的價格上限可能會對公司造成重大損害。儘管數個州建立了類似的委員會以降低藥物成本，但科羅拉多州設定價格限制的嘗試已被法院阻止。

From an economic perspective, the widespread use of GLP-1 drugs is expected to cause major changes in society. Data from PwC shows that household use doubled between early 2025 and mid-2026, and they predict that 50% to 75% of the population could use these drugs within ten years. Consequently, consumer habits are changing; people are buying fewer high-calorie snacks and sugary drinks, while buying more fresh produce and new clothes. Additionally, some evidence suggests that these medications may help women find better employment opportunities, although more research is needed to prove this.

從經濟角度來看，GLP-1 藥物的廣泛使用預計將引起社會重大變化。PwC 的數據顯示，家庭使用量在 2025 年初至 2026 年中之間翻了一倍，並預測在十年內，可能有 50% 到 75% 的人口會使用這些藥物。因此，消費者習慣正在改變；人們購買的高熱量零食和含糖飲料減少，而新鮮農產品和新衣物的購買量增加。此外，一些證據表明這些藥物可能幫助女性獲得更好的就業機會，儘管仍需要更多研究來證明。

In summary, weight-loss medications are becoming much more affordable due to federal programs, while pharmaceutical companies are maintaining their ability to set prices thanks to court decisions.

總之，由於聯邦計劃，減重藥物變得更加可負擔，而製藥公司則多虧法院裁決，得以維持其定價能力。